Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial.

Ward K, Li V, Ramanathan S, Hall LA, Buzzard K, Young K, Mckay F, Vigar V, Oishi S, Madrid San Martin L, Kaskow B, Parnell G, Campbell JA, Sun J, Smith C, Jokubaitis V, Kalincik T, Tscharke D, Potter A, Brady E, Lechner-Scott J, Steinman L, Parmar M, Chataway J, Hardy T, Carroll WM, Barnett MH, Taylor BV, Broadley SA, Australian Multiple Sclerosis Clinical Trials Consortium

Open source

DOI: 10.1136/bmjno-2025-001313
Published: 2025
Container: BMJ neurology open
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjno-2025-001313,
  title = {Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial.},
  author = {Ward K and Li V and Ramanathan S and Hall LA and Buzzard K and Young K and Mckay F and Vigar V and Oishi S and Madrid San Martin L and Kaskow B and Parnell G and Campbell JA and Sun J and Smith C and Jokubaitis V and Kalincik T and Tscharke D and Potter A and Brady E and Lechner-Scott J and Steinman L and Parmar M and Chataway J and Hardy T and Carroll WM and Barnett MH and Taylor BV and Broadley SA and Australian Multiple Sclerosis Clinical Trials Consortium},
  year = {2025},
  journal = {BMJ neurology open},
  doi = {10.1136/bmjno-2025-001313},
  url = {https://doi.org/10.1136/bmjno-2025-001313}
}

RIS

TY  - JOUR
TI  - Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial.
AU  - Ward K
AU  - Li V
AU  - Ramanathan S
AU  - Hall LA
AU  - Buzzard K
AU  - Young K
AU  - Mckay F
AU  - Vigar V
AU  - Oishi S
AU  - Madrid San Martin L
AU  - Kaskow B
AU  - Parnell G
AU  - Campbell JA
AU  - Sun J
AU  - Smith C
AU  - Jokubaitis V
AU  - Kalincik T
AU  - Tscharke D
AU  - Potter A
AU  - Brady E
AU  - Lechner-Scott J
AU  - Steinman L
AU  - Parmar M
AU  - Chataway J
AU  - Hardy T
AU  - Carroll WM
AU  - Barnett MH
AU  - Taylor BV
AU  - Broadley SA
AU  - Australian Multiple Sclerosis Clinical Trials Consortium
PY  - 2025
JO  - BMJ neurology open
DO  - 10.1136/bmjno-2025-001313
UR  - https://doi.org/10.1136/bmjno-2025-001313
ER  -

APA

K, W., V, L., S, R., LA, H., K, B., K, Y., F, M., V, V., S, O., L, M. S. M., B, K., G, P., JA, C., J, S., C, S., V, J., T, K., D, T., A, P., E, B., J, L., L, S., M, P., J, C., T, H., WM, C., MH, B., BV, T., SA, B., & Consortium, A. M. S. C. T. (2025). Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial.. BMJ neurology open. https://doi.org/10.1136/bmjno-2025-001313

Source records

pubmed · retrieved 2026-09-26T20:00:32.143Z
europe-pmc · retrieved 2026-09-26T20:00:32.151Z
doaj · retrieved 2026-09-26T20:00:32.150Z